-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest news, Moderna is actively preparing to launch a three-in-one vaccine by fall 2023, which will be effective against both COVID-19 and influenza, and also prevent respiratory syncytial virus (RSV) infection
.
Speaking at the World Economic Forum a few days ago, Moderna CEO Stéphane Bancel said that Moderna will develop an annual booster three-in-one vaccine to eliminate the need for people to get two or three shots each time winter approaches.
.
Bancel did not provide any details on the timeline for the release of the triple vaccine, other than predicting that it could be released next year
Moderna's COVID-19 booster injection is currently undergoing multiple Phase III studies, while its efficacy and safety as an influenza treatment is still being developed and may enter Phase III trials in the next few months
.
Last September, Moderna also hinted at the possibility of using the same vaccine for respiratory syncytial virus and other similar respiratory diseases
Currently, COVID-19, influenza and RSV all have their own separate vaccines and booster doses
.
By combining the three indications into one, Moderna hopes the new three-in-one vaccine will make the vaccination process simpler and more convenient for everyone
Most vaccine stocks tumbled on Thursday when the U.
S.
Supreme Court blocked President Biden's mandated Covid-19 vaccinations for workers at large companies
.
Moderna co-founder Noubar Afeyan said in an interview last week that Covid-19 is likely to turn into an endemic in 2022
In addition, in the face of the menacing new variant Omicron, the true protective power of Pfizer and Moderna vaccines has once again been questioned
.
Israel's Sheba Hospital announced Monday that preliminary clinical trials showed that a fourth dose of the Pfizer or Moderna Covid-19 vaccine did not provide effective protection against the mutant strain of Omicron
At present, Moderna's new crown vaccine for the Omicron variant is nearly completed and is about to enter the clinical development stage.
It is expected that data will be submitted to the US regulatory agency in March this year
.
Moderna produced a total of 807 million doses of the new crown vaccine last year, a quarter of which were sent to low- and middle-income countries
Original in English: https:// href="https://" target="_blank">https://
